IDH2 and glioblastoma: Additionally, key molecular alterations, including EGFR amplification, IDH mutations, O6-methylguanine-DNA methyltransferase (MGMT) modifications, histone epigenetic changes and signaling pathway dysregulation, are being examined for their contributions to the aggressive behavior and treatment challenges of GBM.